“…Another vital element is the development of funding options for digital therapeutics during and after the research phase (eg, innovation and research grants, pay-for-performance constructs, or payment/completed digital therapeutic use cycle). For the latter, it is important that the financial responsibility is not placed on patients to protect them from disproportionate out-of-pocket payments and ensure that digital therapeutics do not become an exclusive domain of higher socioeconomic groups [ 12 , 15 , 46 , 58 , 61 , 72 , 86 , 99 , 100 , 105 , 106 , 114 , 116 , 146 , 149 , 154 , 164 , 172 , 190 , 192 , 197 , 200 , 202 , 226 - 228 , 249 ]. It was emphasized that there were benefits to allowing the procurement of digital therapeutics as locally as possible, as health purchasers (eg, Integrated Care Boards in the United Kingdom, insurance companies in the Netherlands, and employer groups in the United States) are best placed to assess the needs and preferences of their covered population, although this could translate into longer adoption times and higher uptake costs, as each individual insurer needs to invest in the digital infrastructure.…”